• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO KG PROSA WITH PROGAV 2.0 AND PED.PRECHAMBER; HYDROCEPHALUS MANAGEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO KG PROSA WITH PROGAV 2.0 AND PED.PRECHAMBER; HYDROCEPHALUS MANAGEMENT Back to Search Results
Model Number FX995T
Medical Device Problem Code Infusion or Flow Problem (2964)
Health Effect - Clinical Code Hydrocephalus (3272)
Date of Event 07/11/2024
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Visual inspection: during the investigation, deposits on the devices were determined.Permeability test: a permeability test has shown that all components are permeable.Computer controlled test: to investigate the claim of under-drainage, the opening pressure is measured using a miethke computer controlled testing apparatus which simulates a cerebrospinal fluid flow.The valves are tested in both the horizontal as well as the vertical positions.The results show that the valves operate within the permissible tolerance in their respective relevant positions.Adjustment test: both valves were tested, the prosa was not adjustable while the progav 2.0 was adjustable to all pressure ranges.Braking force and brake function test: the brake function test has shown that the brake function on the prosa works as expected; however, the breaking force cannot be measured due to the non-adjustability of the valve.The brake function test of the progav has shown that the brake function works as expected and the braking force is within the specified tolerances.Internal inspection: after dismantling of the valves, deposits were found in both valves.Results: in advance, we would like to point out that the product sent in was not inserted in liquid at the time of delivery.Dried deposits can influence the function of the products, which can affect the results.Despite this, we have examined the valve.Based on our investigation results, we can determine that the prosa is not adjustable.The visible deposits found in the valve are the cause of the functional impairment.Furthermore, we were able to detect visible deposits in the progav 2.0 and on/in the ped.Pre-chamber.These deposits did not affect the technical properties at the time of the examination.Deposits caused by natural substances in the body, such as protein, blood or tissue particles, are among the known and unavoidable risks and side effects of hydrocephalus therapy.Even small amounts of proteins can impair the integrity of the valve.We can exclude a defect at the time of release.The shunt system met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required from our point of view.
 
Event or Problem Description
It was reported that a prosa shunt system (#fx995t) was implanted during a procedure performed on (b)(6) 2024.According to the complainant, the shunt system showed an under-drainage.The patient underwent a revision procedure performed on (b)(6) 2024.The complainant device has returned to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.Age: 1 years, 4 months.Weight: unknown.Height: unknown.Gender: male.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROSA WITH PROGAV 2.0 AND PED.PRECHAMBER
Common Device Name
HYDROCEPHALUS MANAGEMENT
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM  14469
Manufacturer (Section G)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM   14469
Manufacturer Contact
joerg knebel
ulanenweg 2
potsdam, 14469
GM   14469
MDR Report Key20054017
Report Number3004721439-2024-00253
Device Sequence Number18172145
Product Code JXG
UDI-Device Identifier04041906138547
UDI-Public4041906138547
Combination Product (Y/N)N
Initial Reporter CountryGM
PMA/510(K) Number
K161853
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2024
Device Explanted Year2024
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Foreign,User Facility,Company Representative
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date (Section B) 08/23/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date03/12/2023
Device Model NumberFX995T
Device Catalogue NumberFX995T
Device Lot Number20064589
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer08/02/2024
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 08/02/2024
Initial Report FDA Received Date08/23/2024
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured03/13/2023
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age16 MO
Patient SexMale
-
-